January 2019 FDA Recall Drug by Mylan Institutional, Inc. (d.b.a. Udl Laboratories) (D-1013-2019 - Failed Impurities/Degradation Specifications)

This Class II drug recall was voluntarily initiated by Mylan Institutional, Inc. (d.b.a. Udl Laboratories) on January 18, 2019 for the product Drug. The FDA reported the reason for recall as failed impurities/degradation specifications. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-1013-2019

Reason for Recall
Failed Impurities/Degradation Specifications: Elevated levels of a known impurity detected during 6-month RT stability interval.
Initiated
01-18-2019
Reported
03-27-2019
Quantity
10,281 UD cartons

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Mylan Institutional, Inc. (d.b.a. UDL Laboratories)
Nationwide USA and Puerto Rico
Alprazolam Tablets, USP, 0.25 mg, 10x10 per carton, Rx Only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA. NDC: 51079-788-20

Batch or Lot Expiration Information

Lot# Lots: 3095198, 3096266, 3098776, EXP 05-2019